The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases
Open accessAbstract
BACKGROUNDUndifferentiated systemic autoinflammatory diseases (USAIDs) present diagnostic and therapeutic challenges. Chronic interferon (IFN) signaling and cytokine dysregulation may identify diseases with available targeted treatments.METHODSSixty-six consecutively referred USAID patients underwent underwent screening for the presence of an interferon signature using a standardized type-I IFN-response-gene score (IRG-S), cytokine profiling, and genetic evaluation by next-generation sequencing.RESULTSThirty-six USAID patients (55%) had elevated IRG-S. Neutrophilic panniculitis (40% vs. 0%), basal ganglia calcifications (46% vs. 0%), interstitial lung disease (47% vs. 5%), and myositis (60% vs. 10%) were more prevalent in patients with elevated IRG-S. Moderate IRG-S elevation and highly elevated serum IL-18 distinguished 8 patients with pulmonary alveolar proteinosis (PAP) and recurrent macrophage activation syndrome (MAS). Among patients with panniculitis and progressive cytopenias, 2 patients were compound heterozygous for potentially novel LRBA mutations, 4 patients harbored potentially novel splice variants in IKBKG (which encodes NF-κB essential modulator [NEMO]), and 6 patients had de novo frameshift mutations in SAMD9L. Of additional 12 patients with elevated IRG-S and CANDLE-, SAVI- or Aicardi-Goutières syndrome-like (AGS-like) phenotypes, 5 patients carried mutations in either SAMHD1, TREX1, PSMB8, or PSMG2. Two patients had anti-MDA5 autoantibody-positive juvenile dermatomyositis, and 7 could not be classified. Patients with LRBA, IKBKG, and SAMD9L mutations showed a pattern of IRG elevation that suggests prominent NF-κB activation different from the canonical interferonopathies CANDLE, SAVI, and AGS.CONCLUSIONSIn patients with elevated IRG-S, we identified characteristic clinical features and 3 additional autoinflammatory diseases: IL-18-mediated PAP and recurrent MAS (IL-18PAP-MAS), NEMO deleted exon 5-autoinflammatory syndrome (NEMO-NDAS), and SAMD9L-associated autoinflammatory disease (SAMD9L-SAAD). The IRG-S expands the diagnostic armamentarium in evaluating USAIDs and points to different pathways regulating IRG expression.TRIAL REGISTRATIONClinicalTrials.gov NCT02974595.FUNDINGThe Intramural Research Program of the NIH, NIAID, NIAMS, and the Clinical Center.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trex1 prevents cell-intrinsic initiation of autoimmunity
Stetson, D. B., Ko, J. S., Heidmann, T., & Medzhitov, R. (2008) · Cell · doi:10.1016/j.cell.2008.06.032 · Cited by 1,280
Rice, G., Newman, W. G., Dean, J., Patrick, T., Parmar, R., Flintoff, K., Robins, P., Harvey, S., Hollis, T., O’Hara, A., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/513443 · Cited by 410 · cited 1×
“Patient G7-P3 had severe localized panniculitis, localized lipoatrophy, and basal ganglia calcifications without white matter disease, and harbored a de novo somatic mutation (~26% allele fraction) in TREX1 that was previously associated with autosomal dominant AGS1 as a germline mutation (29).”
BackgroundSevere imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome
Mazodier, K. (2005) · Blood · doi:10.1182/blood-2005-05-1980 · Cited by 290
Leptin Deficiency Causes Insulin Resistance Induced by Uncontrolled Diabetes
German, J. P., Wisse, B. E., Thaler, J. P., Oh-I, S., Sarruf, D. A., Ogimoto, K., Kaiyala, K. J., Fischer, J. D., Matsen, M. E., Taborsky, G. J., et al. (2010) · Diabetes · doi:10.2337/db09-1918 · Cited by 159
Shimizu, M., Nakagishi, Y., & Yachie, A. (2013) · Cytokine · doi:10.1016/j.cyto.2012.11.025 · Cited by 128
Cited by
Fajgenbaum, D. C., & June, C. H. (2020) · New England Journal of Medicine · doi:10.1056/nejmra2026131 · Cited by 3,196
Tangye, S. G., Al-Herz, W., Bousfiha, A., Cunningham-Rundles, C., Franco, J. L., Holland, S. M., Klein, C., Morio, T., Oksenhendler, E., Picard, C., et al. (2022) · Journal of Clinical Immunology · doi:10.1007/s10875-022-01289-3 · Cited by 1,156
Self-citationDeath by TNF: a road to inflammation
van Loo, G., & Bertrand, M. J. M. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00792-3 · Cited by 926
Jamilloux, Y., Henry, T., Belot, A., Viel, S., Fauter, M., El Jammal, T., Walzer, T., François, B., & Sève, P. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102567 · Cited by 658
Hemophagocytic lymphohistiocytosis: An update on pathogenesis, diagnosis, and therapy
Griffin, G., Shenoi, S., & Hughes, G. C. (2020) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2020.101515 · Cited by 349
Metadata
- Authors
- de Jesus, A. A., Hou, Y., Brooks, S., Malle, L., Biancotto, A., Huang, Y., Calvo, K. R., Marrero, B., Moir, S., Oler, A. J., Deng, Z., Montealegre Sanchez, G. A., Ahmed, A., Allenspach, E., Arabshahi, B., Behrens, E., Benseler, S., Bezrodnik, L., Bout-Tabaku, S., Brescia, A. C., Brown, D., Burnham, J. M., Caldirola, M. S., Carrasco, R., Chan, A. Y., Cimaz, R., Dancey, P., Dare, J., DeGuzman, M., Dimitriades, V., Ferguson, I., Ferguson, P., Finn, L., Gattorno, M., Grom, A. A., Hanson, E. P., Hashkes, P. J., Hedrich, C. M., Herzog, R., Horneff, G., Jerath, R., Kessler, E., Kim, H., Kingsbury, D. J., Laxer, R. M., Lee, P. Y., Lee-Kirsch, M. A., Lewandowski, L., Li, S., Lilleby, V., Mammadova, V., Moorthy, L. N., Nasrullayeva, G., O’Neil, K. M., Onel, K., Ozen, S., Pan, N., Pillet, P., Piotto, D. G. P., Punaro, M. G., Reiff, A., Reinhardt, A., Rider, L. G., Rivas-Chacon, R., Ronis, T., Rösen-Wolff, A., Roth, J., Ruth, N. M., Rygg, M., Schmeling, H., Schulert, G., Scott, C., Seminario, G., Shulman, A., Sivaraman, V., Son, M. B., Stepanovskiy, Y., Stringer, E., Taber, S., Terreri, M. T., Tifft, C., Torgerson, T., Tosi, L., Van Royen-Kerkhof, A., Wampler Muskardin, T., Canna, S. W., & Goldbach-Mansky, R.
- Venue
- Journal of Clinical Investigation
- Published
- 2020-02-24
- Volume
- 130
- Issue
- 4
- Pages
- 1669-1682
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W2997784912
- Cited by
- 239
- References
- 5
- FWCI
- 7.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.